Actavis Group, the international generic pharmaceuticals company, will be participating in the Congress of the European Association of Hospital Pharmacists (EAHP) in Maastricht, beginning today.
The Annual Congress of the EAHP is the largest hospital pharmacy meeting in Europe, reportedly attended by some 2,000 colleagues from all over the world.
Actavis has set its sights firmly on the hospital sector and currently has around 300 pending applications worldwide for injectable medicines. Furthermore, Actavis’ ambitious pipeline comprises more than 60 new projects, developed both internally and through established relationships with other developers.
Actavis already markets over 50 hospital products, with a focus on oncology products and a growing range of anti-infectives, local anaesthetics and analgesics. Recently Actavis signed an agreement with Pfizer to acquire a manufacturing site specialising in the production of oncology products. The site, which covers an area of 300,000 square metres, is located in Nerviano, Italy. At the same time Actavis entered into a multi-year exclusive agreement with Pfizer for the supply of oncology products.
Actavis has further extended its portfolio through the acquisition of Floxapen from GSK, as well as Reteplase (rapsylin) and Isotretenoin (acitretin) from Roche. Actavis’ exclusive rights agreement to distribute and sell the Deltaselect injectable range in Germany and other select countries came into effect in October 2007.
This transaction has established Actavis as a major player in the German hospital market. Actavis currently markets over 30 molecules from the Deltaselect portfolio in the German market and plans are in place to introduce up to eight complementary molecules over the coming year. Work is also already underway to register and sell these products in a number of other countries.
Robert Wessman, President and CEO, said:
“Actavis is already renowned for fast access to high quality, affordable generics. We are excited and pleased to be extending our product range to hospitals throughout Europe. We look forward to being of service to hospital pharmacists over the coming years.”